Advertisement

Hyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State

  • Guillermo E. Umpierrez
Reference work entry
Part of the Endocrinology book series (ENDOCR)

Abstract

Diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar state (HHS) are the two most serious hyperglycemic emergencies in patients with diabetes mellitus. DKA most often occurs in patients with type 1 diabetes, but patients with type 2 diabetes are susceptible to DKA under stressful conditions such as trauma, surgery or infections. HHS is more common in adult and elderly patients with poorly controlled type 2 diabetes. In the U.S., the number of admissions for DKA has increased during the past decade to ∼165,000 cases of each year. The rate of hospitalization for HHS is significantly lower, accounting for < 1% of all diabetes related admissions. DKA and HHS are characterized by insulinopenia and severe hyperglycemia; clinically, these two conditions differ by severity of metabolic acidosis, dehydration, metabolic acidosis and ketonemia. The overall mortality recorded among adults is < 1–2% in patients with DKA and ∼10–15% in patients with HHS. Management objectives for DKA and HHS include restoration of circulatory volume and tissue perfusion; correction of hyperglycemia, ketogenesis and electrolyte imbalance; and identification and treatment of the precipitating event. This review describes the clinical presentation, precipitating causes, diagnosis and acute management of these diabetic emergencies, and of practical strategies for their prevention.

Keywords

Hyperglycemic emergencies Ketoacidosis Diabetic emergencies 

References

  1. Abramson E, Arky R. Diabetic acidosis with initial hypokalemia. Therapeutic implications. JAMA. 1966;196(5):401–3.CrossRefGoogle Scholar
  2. Adrogue HJ, Lederer ED, Suki WN, Eknoyan G. Determinants of plasma potassium levels in diabetic ketoacidosis. Medicine (Baltimore). 1986;65(3):163–72.CrossRefGoogle Scholar
  3. American Diabetes Association. Type 2 diabetes in children and adolescents. Pediatrics. 2000;105(3 Pt 1):671–80.CrossRefGoogle Scholar
  4. Ananth J, Parameswaran S, Gunatilake S. Side effects of atypical antipsychotic drugs. Curr Pharm Des. 2004;10(18):2219–29.CrossRefGoogle Scholar
  5. Arieff AI, Carroll HJ. Hyperosmolar nonketotic coma with hyperglycemia: abnormalities of lipid and carbohydrate metabolism. Metabolism. 1971;20(6):529–38.CrossRefGoogle Scholar
  6. Balasubramanyam A, Zern JW, Hyman DJ, Pavlik V. New profiles of diabetic ketoacidosis: type 1 vs type 2 diabetes and the effect of ethnicity. Arch Intern Med. 1999;159(19):2317–22.CrossRefGoogle Scholar
  7. Banerji MA, Chaiken RL, Huey H, et al. GAD antibody negative NIDDM in adult black subjects with diabetic ketoacidosis and increased frequency of human leukocyte antigen DR3 and DR4. Flatbush diabetes. Diabetes. 1994;43(6):741–5.CrossRefGoogle Scholar
  8. Banerji MA, Chaiken RL, Lebovitz HE. Prolongation of near-normoglycemic remission in black NIDDM subjects with chronic low-dose sulfonylurea treatment. Diabetes. 1995;44(4):466–70.CrossRefGoogle Scholar
  9. Bas VN, Uytun S, Torun YA. Diabetic euglycemic ketoacidosis in newly diagnosed type 1 diabetes mellitus during Ramadan fasting. J Pediatr Endocrinol Metab. 2015;28(3–4):333–5.PubMedGoogle Scholar
  10. Basu A, Close CF, Jenkins D, Krentz AJ, Nattrass M, Wright AD. Persisting mortality in diabetic ketoacidosis. Diabet Med. 1993;10(3):282–4.CrossRefGoogle Scholar
  11. Beigelman PM. Potassium in severe diabetic ketoacidosis. Am J Med. 1973;54(4):419–20.CrossRefGoogle Scholar
  12. Ben Salem C, Fathallah N, Hmouda H, Bouraoui K. Drug-induced hypoglycaemia: an update. Drug Saf. 2011;34(1):21–45.CrossRefGoogle Scholar
  13. Bhowmick SK, Levens KL, Rettig KR. Hyperosmolar hyperglycemic crisis: an acute life-threatening event in children and adolescents with type 2 diabetes mellitus. Endocr Pract. 2005;11(1):23–9.CrossRefGoogle Scholar
  14. Buse JB, Cavazzoni P, Hornbuckle K, Hutchins D, Breier A, Jovanovic L. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol. 2003;56(2):164–70.CrossRefGoogle Scholar
  15. Cahill GF Jr. Fuel metabolism in starvation. Annu Rev Nutr. 2006;26:1–22.CrossRefGoogle Scholar
  16. Caro JJ, Ward A, Levinton C, Robinson K. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry. 2002;63(12):1135–9.CrossRefGoogle Scholar
  17. Centers for Disease Control and Prevention, Department of Health and Human Services: Diabetes Data & Trends. Crude and Age-Adjusted Hospital Discharge Rates for Diabetic Ketoacidosis as First-Listed Diagnosis per 1,000 Diabetic Population, United States. 1988–2009. http://www.cdc.gov/diabetes/statistics/dkafirst/. Accessed 1/2013.
  18. Centers for Disease Control and Prevention. Mortality due to Hyperglycemic crises. http://www.cdc.gov/diabetes/statistics/complications_national.htm. 2013. Accessed on 2 Sept 2016.
  19. Chaudhuri A, Umpierrez GE. Oxidative stress and inflammation in hyperglycemic crises and resolution with insulin: implications for the acute and chronic complications of hyperglycemia. J Diabetes Complicat. 2012;26(4):257–8.CrossRefGoogle Scholar
  20. Davis SN, Umpierrez GE. Diabetic ketoacidosis in type 2 diabetes mellitus – pathophysiology and clinical presentation. Nat Clin Pract Endocrinol Metab. 2007;3(11):730–1.CrossRefGoogle Scholar
  21. Deeb A, Yousef H, Abdelrahman L, et al. Implementation of a diabetes educator care model to reduce paediatric admission for diabetic ketoacidosis. J Diabetes Res. 2016;2016:3917806.CrossRefGoogle Scholar
  22. DeFronzo RA, Matzuda M, Barret E. Diabetic ketoacidosis: a combined metabolic-nephrologic approach to therapy. Diabetes Rev. 1994;2:209–38.Google Scholar
  23. Ennis ED, Stahl EJVB, Kreisberg RA. The hyperosmolar hyperglycemic syndrome. Diabetes Rev. 1994;2:115–26.Google Scholar
  24. Erondu N, Desai M, Ways K, Meininger G. Diabetic ketoacidosis and related events in the Canagliflozin type 2 diabetes clinical program. Diabetes Care. 2015;38(9):1680–6.CrossRefGoogle Scholar
  25. Ersoz HO, Ukinc K, Kose M, et al. Subcutaneous lispro and intravenous regular insulin treatments are equally effective and safe for the treatment of mild and moderate diabetic ketoacidosis in adult patients. Int J Clin Pract. 2006;60(4):429–33.CrossRefGoogle Scholar
  26. Fadini GP, de Kreutzenberg SV, Rigato M, et al. Characteristics and outcomes of the hyperglycemic hyperosmolar non-ketotic syndrome in a cohort of 51 consecutive cases at a single center. Diabetes Res Clin Pract. 2011;94(2):172–9.CrossRefGoogle Scholar
  27. Fisher JN, Kitabchi AE. A randomized study of phosphate therapy in the treatment of diabetic ketoacidosis. J Clin Endocrinol Metab. 1983;57(1):177–80.CrossRefGoogle Scholar
  28. Foster DW, McGarry JD. The metabolic derangements and treatment of diabetic ketoacidosis. N Engl J Med. 1983;309(3):159–69.CrossRefGoogle Scholar
  29. Fulop M. Alcoholism, ketoacidosis, and lactic acidosis. Diabetes Metab Rev. 1989;5(4):365–78.CrossRefGoogle Scholar
  30. Garg SK, Walker AJ, Hoff HK, D’Souza AO, Gottlieb PA, Chase HP. Glycemic parameters with multiple daily injections using insulin glargine versus insulin pump. Diabetes Technol Ther. 2004;6(1):9–15.CrossRefGoogle Scholar
  31. Gerich JE, Martin MM, Recant L. Clinical and metabolic characteristics of hyperosmolar nonketotic coma. Diabetes. 1971;20(4):228–38.CrossRefGoogle Scholar
  32. Gerich JE, Lorenzi M, Bier DM, et al. Effects of physiologic levels of glucagon and growth hormone on human carbohydrate and lipid metabolism. Studies involving administration of exogenous hormone during suppression of endogenous hormone secretion with somatostatin. J Clin Invest. 1976;57(4):875–84.CrossRefGoogle Scholar
  33. Gianfrancesco F, Grogg A, Mahmoud R, Wang RH, Meletiche D. Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders. Clin Ther. 2003;25(4):1150–71.CrossRefGoogle Scholar
  34. Green SM, Rothrock SG, Ho JD, et al. Failure of adjunctive bicarbonate to improve outcome in severe pediatric diabetic ketoacidosis. Ann Emerg Med. 1998;31(1):41–8.CrossRefGoogle Scholar
  35. Guo RX, Yang LZ, Li LX, Zhao XP. Diabetic ketoacidosis in pregnancy tends to occur at lower blood glucose levels: case-control study and a case report of euglycemic diabetic ketoacidosis in pregnancy. J Obstet Gynaecol Res. 2008;34(3):324–30.CrossRefGoogle Scholar
  36. Diabetes Control and Complications Trial (DCCT). Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care. 1995;18(3):361–76.CrossRefGoogle Scholar
  37. Jefferies CA, Nakhla M, Derraik JG, Gunn AJ, Daneman D, Cutfield WS. Preventing diabetic ketoacidosis. Pediatr Clin N Am. 2015;62(4):857–71.CrossRefGoogle Scholar
  38. Jenkins D, Close CF, Krentz AJ, Nattrass M, Wright AD. Euglycaemic diabetic ketoacidosis: does it exist? Acta Diabetol. 1993;30(4):251–3.CrossRefGoogle Scholar
  39. Johnson SR, Cooper MN, Jones TW, Davis EA. Long-term outcome of insulin pump therapy in children with type 1 diabetes assessed in a large population-based case-control study. Diabetologia. 2013;56(11):2392–400.CrossRefGoogle Scholar
  40. Karoli R, Fatima J, Salman T, Sandhu S, Shankar R. Managing diabetic ketoacidosis in non-intensive care unit setting: role of insulin analogs. Indian J Pharm. 2011;43(4):398–401.CrossRefGoogle Scholar
  41. Kibbey RG. SGLT-2 inhibition and glucagon: cause for alarm? Trends Endocrinol Metab. 2015;26(7):337–8.CrossRefGoogle Scholar
  42. Kim F, Tysseling KA, Rice J, et al. Free fatty acid impairment of nitric oxide production in endothelial cells is mediated by IKKbeta. Arterioscler Thromb Vasc Biol. 2005;25(5):989–94.CrossRefGoogle Scholar
  43. Kitabchi AE. Ketosis-prone diabetes – a new subgroup of patients with atypical type 1 and type 2 diabetes? J Clin Endocrinol Metab. 2003;88(11):5087–9.CrossRefGoogle Scholar
  44. Kitabchi AE, Wall BM. Diabetic ketoacidosis. Med Clin North Am. 1995;79(1):9–37.CrossRefGoogle Scholar
  45. Kitabchi AE, Ayyagari V, Guerra SM. The efficacy of low-dose versus conventional therapy of insulin for treatment of diabetic ketoacidosis. Ann Intern Med. 1976;84(6):633–8.CrossRefGoogle Scholar
  46. Kitabchi AE, Umpierrez GE, Murphy MB, et al. Management of hyperglycemic crises in patients with diabetes. Diabetes Care. 2001;24(1):131–53.CrossRefGoogle Scholar
  47. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009;32(7):1335–43.CrossRefGoogle Scholar
  48. Laffel L. Sick-day management in type 1 diabetes. Endocrinol Metab Clin N Am. 2000;29(4): 707–23.CrossRefGoogle Scholar
  49. Latif KA, Freire AX, Kitabchi AE, Umpierrez GE, Qureshi N. The use of alkali therapy in severe diabetic ketoacidosis. Diabetes Care. 2002;25(11):2113–4.CrossRefGoogle Scholar
  50. Li J, Huang M, Shen X. The association of oxidative stress and pro-inflammatory cytokines in diabetic patients with hyperglycemic crisis. J Diabetes Complicat. 2014;28(5):662–6.CrossRefGoogle Scholar
  51. Lipscombe LL, Austin PC, Alessi-Severini S, et al. Atypical antipsychotics and hyperglycemic emergencies: multicentre, retrospective cohort study of administrative data. Schizophr Res. 2014;154(1–3):54–60.CrossRefGoogle Scholar
  52. Ly TT, Nicholas JA, Retterath A, Lim EM, Davis EA, Jones TW. Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial. JAMA. 2013;310(12):1240–7.CrossRefGoogle Scholar
  53. Maldonado MR, Chong ER, Oehl MA, Balasubramanyam A. Economic impact of diabetic ketoacidosis in a Multiethnic indigent population: analysis of costs based on the precipitating cause. Diabetes Care. 2003a;26(4):1265–9.CrossRefGoogle Scholar
  54. Maldonado M, Hampe CS, Gaur LK, et al. Ketosis-prone diabetes: dissection of a heterogeneous syndrome using an immunogenetic and beta-cell functional classification, prospective analysis, and clinical outcomes. J Clin Endocrinol Metab. 2003b;88(11):5090–8.CrossRefGoogle Scholar
  55. Maldonado MR, Otiniano ME, Lee R, Rodriguez L, Balasubramanyam A. Ethnic differences in beta-cell functional reserve and clinical features in patients with ketosis-prone diabetes. Diabetes Care. 2003c;26(8):2469.CrossRefGoogle Scholar
  56. Malone ML, Gennis V, Goodwin JS. Characteristics of diabetic ketoacidosis in older versus younger adults. J Am Geriatr Soc. 1992;40(11):1100–4.CrossRefGoogle Scholar
  57. Mauvais-Jarvis F, Sobngwi E, Porcher R, et al. Ketosis-prone type 2 diabetes in patients of sub-Saharan African origin: clinical pathophysiology and natural history of beta-cell dysfunction and insulin resistance. Diabetes. 2004;53(3):645–53.CrossRefGoogle Scholar
  58. McDonnell CM, Pedreira CC, Vadamalayan B, Cameron FJ, Werther GA. Diabetic ketoacidosis, hyperosmolarity and hypernatremia: are high-carbohydrate drinks worsening initial presentation? Pediatr Diabetes. 2005;6(2):90–4.CrossRefGoogle Scholar
  59. McFarlane SI, Chaiken RL, Hirsch S, Harrington P, Lebovitz HE, Banerji MA. Near-normoglycaemic remission in African-Americans with type 2 diabetes mellitus is associated with recovery of beta cell function. Diabet Med. 2001;18(1):10–6.CrossRefGoogle Scholar
  60. McGarry JD. Lilly Lecture 1978. New perspectives in the regulation of ketogenesis. Diabetes. 1979;28(5):517–23.CrossRefGoogle Scholar
  61. McGarry JD, Foster DW. Regulation of hepatic fatty acid oxidation and ketone body production. Annu Rev Biochem. 1980;49:395–420.CrossRefGoogle Scholar
  62. McGarry JD, Woeltje KF, Kuwajima M, Foster DW. Regulation of ketogenesis and the renaissance of carnitine palmitoyltransferase. Diabetes Metab Rev. 1989;5(3):271–84.CrossRefGoogle Scholar
  63. Musey VC, Lee JK, Crawford R, Klatka MA, McAdams D, Phillips LS. Diabetes in urban African-Americans. I. Cessation of insulin therapy is the major precipitating cause of diabetic ketoacidosis. Diabetes Care. 1995;18(4):483–9.CrossRefGoogle Scholar
  64. Pasquel FJ, Umpierrez GE. Hyperosmolar hyperglycemic state: a historic review of the clinical presentation, diagnosis, and treatment. Diabetes Care. 2014;37(11):3124–31.CrossRefGoogle Scholar
  65. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38(9):1687–93.CrossRefGoogle Scholar
  66. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 2004;27(3):813–23.CrossRefGoogle Scholar
  67. Polonsky WH, Anderson BJ, Lohrer PA, Aponte JE, Jacobson AM, Cole CF. Insulin omission in women with IDDM. Diabetes Care. 1994;17(10):1178–85.CrossRefGoogle Scholar
  68. Rains JL, Jain SK. Oxidative stress, insulin signaling, and diabetes. Free Radic Biol Med. 2011;50(5):567–75.CrossRefGoogle Scholar
  69. Randall L, Begovic J, Hudson M, et al. Recurrent diabetic ketoacidosis in inner-city minority patients: behavioral, socioeconomic, and psychosocial factors. Diabetes Care. 2011;34(9): 1891–6.CrossRefGoogle Scholar
  70. Rydall AC, Rodin GM, Olmsted MP, Devenyi RG, Daneman D. Disordered eating behavior and microvascular complications in young women with insulin-dependent diabetes mellitus. N Engl J Med. 1997;336(26):1849–54.CrossRefGoogle Scholar
  71. Shen T, Braude S. Changes in serum phosphate during treatment of diabetic ketoacidosis: predictive significance of severity of acidosis on presentation. Intern Med J. 2012;42(12):1347–50.CrossRefGoogle Scholar
  72. Shen XP, Li J, Zou S, Wu HJ, Zhang Y. The relationship between oxidative stress and the levels of serum circulating adhesion molecules in patients with hyperglycemia crises. J Diabetes Complicat. 2012;26(4):291–5.CrossRefGoogle Scholar
  73. Sobngwi E, Gautier JF. Adult-onset idiopathic type I or ketosis-prone type II diabetes: evidence to revisit diabetes classification. Diabetologia. 2002;45(2):283–5.CrossRefGoogle Scholar
  74. Sobngwi E, Vexiau P, Levy V, et al. Metabolic and immunogenetic prediction of long-term insulin remission in African patients with atypical diabetes. Diabet Med. 2002a;19(10):832–5.CrossRefGoogle Scholar
  75. Sobngwi E, Mauvais-Jarvis F, Vexiau P, Mbanya JC, Gautier JF. Diabetes in Africans. Part 2: ketosis-prone atypical diabetes mellitus. Diabetes Metab. 2002b;28(1):5–12.PubMedGoogle Scholar
  76. Stentz FB, Umpierrez GE, Cuervo R, Kitabchi AE. Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes. 2004;53(8):2079–86.CrossRefGoogle Scholar
  77. Stephens JM, Sulway MJ, Watkins PJ. Relationship of blood acetoacetate and 3-hydroxybutyrate in diabetes. Diabetes. 1971;20(7):485–9.CrossRefGoogle Scholar
  78. Tang H, Li D, Wang T, Zhai S, Song Y. Effect of sodium-glucose cotransporter 2 inhibitors on diabetic ketoacidosis among patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Care. 2016;39(8):e123–4.CrossRefGoogle Scholar
  79. Taylor SI, Blau JE, Rother KI. Perspective: SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metabol. 2015a.  https://doi.org/10.1210/jc.2015-1884.CrossRefGoogle Scholar
  80. Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab. 2015b;100(8):2849–52.CrossRefGoogle Scholar
  81. Umpierrez G, Freire AX. Abdominal pain in patients with hyperglycemic crises. J Crit Care. 2002;17(1):63–7.CrossRefGoogle Scholar
  82. Umpierrez G, Korytkowski M. Diabetic emergencies – ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. Nat Rev Endocrinol. 2016;12(4):222–32.CrossRefGoogle Scholar
  83. Umpierrez GE, Casals MM, Gebhart SP, Mixon PS, Clark WS, Phillips LS. Diabetic ketoacidosis in obese African-Americans. Diabetes. 1995;44(7):790–5.CrossRefGoogle Scholar
  84. Umpierrez GE, Kelly JP, Navarrete JE, Casals MM, Kitabchi AE. Hyperglycemic crises in urban blacks. Arch Intern Med. 1997a;157(6):669–75.CrossRefGoogle Scholar
  85. Umpierrez GE, Clark WS, Steen MT. Sulfonylurea treatment prevents recurrence of hyperglycemia in obese African-American patients with a history of hyperglycemic crises. Diabetes Care. 1997b;20(4):479–83.CrossRefGoogle Scholar
  86. Umpierrez GE, Woo W, Hagopian WA, et al. Immunogenetic analysis suggests different pathogenesis for obese and lean African-Americans with diabetic ketoacidosis. Diabetes Care. 1999;22(9):1517–23.CrossRefGoogle Scholar
  87. Umpierrez GE, DiGirolamo M, Tuvlin JA, Isaacs SD, Bhoola SM, Kokko JP. Differences in metabolic and hormonal milieu in diabetic- and alcohol- induced ketoacidosis. J Crit Care. 2000;15(2):52–9.CrossRefGoogle Scholar
  88. Umpierrez GE, Latif K, Stoever J, et al. Efficacy of subcutaneous insulin lispro versus continuous intravenous regular insulin for the treatment of patients with diabetic ketoacidosis. Am J Med. 2004a;117(5):291–6.CrossRefGoogle Scholar
  89. Umpierrez GE, Cuervo R, Karabell A, Latif K, Freire AX, Kitabchi AE. Treatment of diabetic ketoacidosis with subcutaneous insulin aspart. Diabetes Care. 2004b;27(8):1873–8.CrossRefGoogle Scholar
  90. Umpierrez GE, Smiley D, Kitabchi AE. Narrative review: ketosis-prone type 2 diabetes mellitus. Ann Intern Med. 2006;144(5):350–7.CrossRefGoogle Scholar
  91. Umpierrez GE, Jones S, Smiley D, et al. Insulin analogs versus human insulin in the treatment of patients with diabetic ketoacidosis: a randomized controlled trial. Diabetes Care. 2009;32(7): 1164–9.CrossRefGoogle Scholar
  92. Vaarala O, Yki-Jarvinen H. Diabetes: should we treat infection or inflammation to prevent T2DM? Nat Rev Endocrinol. 2012;8(6):323–5.CrossRefGoogle Scholar
  93. Vanelli M, Chiari G, Ghizzoni L, Costi G, Giacalone T, Chiarelli F. Effectiveness of a prevention program for diabetic ketoacidosis in children. An 8-year study in schools and private practices. Diabetes Care. 1999;22(1):7–9.CrossRefGoogle Scholar
  94. Vellanki P, Smiley DD, Stefanovski D, et al. Randomized controlled study of metformin and Sitagliptin on long-term Normoglycemia remission in African American patients with Hyperglycemic crises. Diabetes Care. 2016;39(11):1948–55.CrossRefGoogle Scholar
  95. Wilson HK, Keuer SP, Lea AS, Boyd AE 3rd, Eknoyan G. Phosphate therapy in diabetic ketoacidosis. Arch Intern Med. 1982;142(3):517–20.CrossRefGoogle Scholar
  96. Winter RJ, Harris CJ, Phillips LS, Green OC. Diabetic ketoacidosis. Induction of hypocalcemia and hypomagnesemia by phosphate therapy. Am J Med. 1979;67(5):897–900.CrossRefGoogle Scholar
  97. Wrenn KD, Slovis CM, Minion GE, Rutkowski R. The syndrome of alcoholic ketoacidosis. Am J Med. 1991;91(2):119–28.CrossRefGoogle Scholar
  98. Yamada K, Nonaka K. Diabetic ketoacidosis in young obese Japanese men. Diabetes Care. 1996;19(6):671.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Medicine, Division of Endocrinology and MetabolismEmory University School of MedicineAtlantaUSA

Personalised recommendations